| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5883003 | Clinical Lymphoma Myeloma and Leukemia | 2015 | 6 Pages |
Abstract
The outcomes in our routinely treated FL patients confirm the benefit of adding rituximab to chemotherapy and are comparable to the results of pivotal clinical studies. The outcome of our FL patients was improved in terms of both PFS and OS.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Tanja JužniÄ Å etina, Simona BorÅ¡tnar, Barbara JezerÅ¡ek NovakoviÄ,